CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:A single-centre retrospective study investigating changes in nutritional status and use of dietetic interventions in children receiving chimeric antigen receptor T-cell therapy.
A single-centre retrospective study investigating changes in nutritional status and use of dietetic interventions in children receiving chimeric antigen receptor T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
尽管儿童体重有适度下降,但大多数需要饮食干预来支持,最常见的是口服营养补充剂和管饲。主动让家庭为管饲做好准备对于促进接受至关重要。未接受饮食干预的儿童可能本可从饮食指导中获益。随着越来越多证据表明营养状态变化及其对结局的影响,饮食指导对于制定营养支持算法至关重要,以指导接受 CAR-T 的儿童的筛查、评估和干预的使用。
CAR-T 细胞疗法(CAR-T)是治疗儿童复发/难治性急性淋巴细胞白血病的一种新型疗法。儿童在癌症治疗期间维持营养状态可显示出更优的结局。很少有研究探讨CAR-T 对儿童营养状态的影响。本研究旨在考察接受CAR-T 治疗的儿童的营养状态及饮食干预的使用情况。
回顾性审查了2015年6月至2024年6月期间在伦敦大奥蒙德街医院接受CAR-T 治疗的所有儿童的电子记录。在儿童因CAR-T 住院期间检查了营养结局,包括体重变化和使用的饮食干预措施,包括口服营养补充剂、肠内管饲和肠外营养。分析了不同干预措施对儿童体重变化和住院时间的影响。
132 名儿童接受了 CAR-T,65% 为男性,平均年龄 8 岁。从 CAR-T 细胞输注到出院期间的体重变化为平均下降 -1.8%。62% 需要饮食干预,其中 45% 接受口服营养补充剂,56% 接受肠内管饲(其中 87% 为鼻胃管,13% 为胃造瘘),34% 接受肠外营养。后者主要因无法耐受管饲而启动,平均提供 23 天。接受任何饮食干预的儿童比未接受任何饮食干预的儿童体重增加更多(+0.7% v -1.6%,p = 0.020),主动启动口服营养补充剂(CAR-T 细胞输注后第 3 天之前)的儿童比被动启动(第 3 天或之后)的儿童也是如此(+0.4% v -3.3%,p = 0.030),主动开始管饲的儿童比被动开始的儿童也是如此(+2.4% v -3.6%,p = 0.027)。未接受任何饮食干预的儿童住院时间比接受干预的儿童更短(19 天 v 30 天,p < 0.001),未接受管饲的儿童比接受管饲的儿童也更短(22 v 32 天,p = 0.001)。
Electronic records of all children who had CAR-T between June 2015-June 2024 at Great Ormond Street Hospital in London were retrospectively reviewed. Nutritional outcomes were examined during the child's admission for CAR-T, including weight change and dietetic interventions used including oral nutritional supplements, enteral tube feeding and parenteral nutrition. Impact of different interventions on children's weight change and length of stay were analysed.
CAR-T was provided to 132 children, 65 % male, mean age eight years. Weight change from CAR T-cell infusion to discharge was a mean loss of -1.8 %. Sixty two percent required a dietetic intervention and of these 45 % received oral nutritional supplements, 56 % enteral tube feeding (of these 87 % had a nasogastric tube, 13 % a gastrostomy), 34 % parenteral nutrition. The latter was initiated primarily for intolerance to tube feeding and provided for a mean 23 days. Children who received any dietetic intervention gained more weight than those who received none (+0.7 % v -1.6 %, p = 0.020), as did those who initiated oral nutritional supplements proactively (before day three post-CAR T-cell infusion) versus reactively (on or after day three) (+0.4 % v -3.3 %, p = 0.030), and those who started tube feeding proactively versus reactively (+2.4 % v -3.6 %, p = 0.027). Length of stay was shorter for children who did not receive any dietetic intervention than those who did (19 days v 30, p < 0.001), and those who did not receive tube feeding versus those who did (22 v 32 days, p = 0.001).
Although children experienced a modest weight loss the majority required a dietetic intervention to support this, most commonly oral nutritional supplements and tube feeding. Proactive preparation of families for tube feeding is essential to facilitate acceptance. Children who did not receive a dietetic intervention may have benefitted from dietetic input. With growing evidence of changes in nutritional status and impact on outcomes, dietetic input is key to develop nutritional support algorithms that guide the use of screening, assessment and interventions in children having CAR-T.
MEMBER ACCOUNT
登录成功会直接打开下一页。